Fallarino F - Search Results

1

Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12.

Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Fallarino F, et al. Int J Cancer. 1999 Jan 18;80(2):324-33. doi: 10.1002/(sici)1097-0215(19990118)80:2<324::aid-ijc25>3.0.co;2-d. Int J Cancer. 1999. PMID: 9935218

2

Antigen-specific regression of established tumors induced by active immunization with irradiated IL-12- but not B7-1-transfected tumor cells.

Fallarino F, Ashikari A, Boon T, Gajewski TF. Fallarino F, et al. Int Immunol. 1997 Sep;9(9):1259-69. doi: 10.1093/intimm/9.9.1259. Int Immunol. 1997. PMID: 9310829

3

Rational development of tumour antigen-specific immunization in melanoma.

Gajewski TF, Fallarino F. Gajewski TF, et al. Among authors: fallarino f. Ther Immunol. 1995 Aug;2(4):211-25. Ther Immunol. 1995. PMID: 9358613 Review.

4

Immunization of HLA-A2+ melanoma patients with MAGE-3 or MelanA peptide-pulsed autologous peripheral blood mononuclear cells plus recombinant human interleukin 12.

Gajewski TF, Fallarino F, Ashikari A, Sherman M. Gajewski TF, et al. Among authors: fallarino f. Clin Cancer Res. 2001 Mar;7(3 Suppl):895s-901s. Clin Cancer Res. 2001. PMID: 11300489 Clinical Trial.

5

Epitope spreading upon P815 tumor rejection triggered by vaccination with the single class I MHC-restricted peptide P1A.

Markiewicz MA, Fallarino F, Ashikari A, Gajewski TF. Markiewicz MA, et al. Among authors: fallarino f. Int Immunol. 2001 May;13(5):625-32. doi: 10.1093/intimm/13.5.625. Int Immunol. 2001. PMID: 11312250

6

Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo.

Fallarino F, Uyttenhove C, Boon T, Gajewski TF. Fallarino F, et al. J Immunol. 1996 Feb 1;156(3):1095-100. J Immunol. 1996. PMID: 8557984

7

B7-1 engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28.

Fallarino F, Fields PE, Gajewski TF. Fallarino F, et al. J Exp Med. 1998 Jul 6;188(1):205-10. doi: 10.1084/jem.188.1.205. J Exp Med. 1998. PMID: 9653097 Free PMC article.

8

Cutting edge: differentiation of antitumor CTL in vivo requires host expression of Stat1.

Fallarino F, Gajewski TF. Fallarino F, et al. J Immunol. 1999 Oct 15;163(8):4109-13. J Immunol. 1999. PMID: 10510345

9

Blockade of T cell activation using a surface-linked single-chain antibody to CTLA-4 (CD152).

Griffin MD, Hong DK, Holman PO, Lee KM, Whitters MJ, O'Herrin SM, Fallarino F, Collins M, Segal DM, Gajewski TF, Kranz DM, Bluestone JA. Griffin MD, et al. Among authors: fallarino f. J Immunol. 2000 May 1;164(9):4433-42. doi: 10.4049/jimmunol.164.9.4433. J Immunol. 2000. PMID: 10779742

10

Cutting edge: spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice.

Kacha AK, Fallarino F, Markiewicz MA, Gajewski TF. Kacha AK, et al. Among authors: fallarino f. J Immunol. 2000 Dec 1;165(11):6024-8. doi: 10.4049/jimmunol.165.11.6024. J Immunol. 2000. PMID: 11086033

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

186 results

Search Page

Filters